evolocumab Repatha
Selected indexed studies
- Evolocumab (Repatha®). (, 1994) [PMID:35951959]
- Evolocumab (Repatha®). (, 1994) [PMID:35951958]
- Long-Term Evolocumab in Patients With Established Atherosclerotic Cardiovascular Disease. (Circulation, 2022) [PMID:36031810]
_Worker-drafted node — pending editorial review._
Connections
No connections recorded yet.
Sources
- Long-Term Evolocumab in Patients With Established Atherosclerotic Cardiovascular Disease. (2022) pubmed
- Clinical Pharmacokinetics and Pharmacodynamics of Evolocumab, a PCSK9 Inhibitor. (2018) pubmed
- Effect of Evolocumab on Coronary Plaque Phenotype and Burden in Statin-Treated Patients Following Myocardial Infarction. (2022) pubmed
- Effect of Evolocumab on Progression of Coronary Disease in Statin-Treated Patients: The GLAGOV Randomized Clinical Trial. (2016) pubmed
- Rationale and design of the effect of evolocumab in patients at high cardiovascular risk without prior myocardial infarction or stroke (VESALIUS-CV) trial. (2024) pubmed
- Evolocumab (Repatha®). (1994) pubmed
- Evolocumab (Repatha®). (1994) pubmed
- PMID:39869742 (2024) pubmed
- Evolocumab. (2006) pubmed
- Lipoprotein(a), PCSK9 Inhibition, and Cardiovascular Risk. (2019) pubmed